Company Profiles

driven by the PitchBook Platform

Presidio Pharmaceuticals

Description

Developer of small-molecule antiviral therapeutics designed to treat hepatitis C virus (HCV) infection. The company's antiviral therapeutics offer once-daily oral dosing and can be combined with other classes of HCV antivirals to combat viral resistance, enabling patients to access effective drug therapies against a variety of known HCV genotypes.

2006

Founded

PRIVATE

Status

11-50

Employees

Series D

Latest Deal Type

$21.8M

Latest Deal Amount

$90.7M

Total Amount Raised

Description

Developer of small-molecule antiviral therapeutics designed to treat hepatitis C virus (HCV) infection. The company's antiviral therapeutics offer once-daily oral dosing and can be combined with other classes of HCV antivirals to combat viral resistance, enabling patients to access effective drug therapies against a variety of known HCV genotypes.

Website:

www.presidiopharma.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Pharmaceuticals

Other Industries

Other Pharmaceuticals and Biotechnology
Drug Discovery

Primary Office

1700 Owens Street Suite 585 San Francisco, CA 94158United States +1 (415) 655-7560
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Presidio Pharmaceuticals's full profile, request a free trial.

    Presidio Pharmaceuticals Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Presidio Pharmaceuticals Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    Presidio Pharmaceuticals Investors (10)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Baker Brothers InvestmentsPE/BuyoutMinority000 0000000 0000
    Bay City CapitalVenture CapitalMinority000 0000000 0000
    Crown Predator HoldingsVenture CapitalMinority000 0000000 0000
    Five Corners CapitalVenture CapitalMinority000 0000000 0000
    MedivirCorporationMinority000 0000000 0000
    Baker Brothers Investments PE/Buyout
    Bay City Capital Venture Capital
    Crown Predator Holdings Venture Capital
    Five Corners Capital Venture Capital
    Medivir Corporation

    Presidio Pharmaceuticals Executive Team (5)

    NameTitleBoard
    Seat
    Contact
    Info
    Leo RedmondChief Financial Officer, Secretary, Board Member & Acting President
    Richard Colonno Ph.DChief Scientific Adviser
    Leping Li Ph.DChemistry Adviser
    Eric RubyRegulatory Affairs Adviser
    Omar Haffar Ph.DCo-Founder & Board Member
    Leo Redmond Chief Financial Officer, Secretary, Board Member & Acting President
    Richard Colonno Ph.D Chief Scientific Adviser
    Leping Li Ph.D Chemistry Adviser
    Eric Ruby Regulatory Affairs Adviser
    Omar Haffar Ph.D Co-Founder & Board Member

    Presidio Pharmaceuticals Board Members (9)

    NameRepresentingRoleSinceContact
    Info
    Dayton MisfeldtBay City CapitalManaging Director000 0000
    Farid GhazzaouiPresidio PharmaceuticalsBoard Member000 0000
    Felix Baker Ph.DBaker Brothers InvestmentsCo-Founder & Managing Partner000 0000
    H. Daniel Perez MDBay City CapitalAdvisor000 0000
    Jack Obijeski Ph.DSelfBoard Member000 0000
    Dayton Misfeldt Managing Director Bay City Capital
    Farid Ghazzaoui Board Member Presidio Pharmaceuticals
    Felix Baker Ph.D Co-Founder & Managing Partner Baker Brothers Investments
    H. Daniel Perez MD Advisor Bay City Capital
    Jack Obijeski Ph.D Board Member Self
    Request full access to PitchBook